At a Glance
- Companies: InterAx Biotech; Alveus Therapeutics
- Location: Switzerland (InterAx); likely US/EU‑based Alveus (metabolic focus)
- Deal value: Undisclosed upfront, milestones and royalties
- Focus area: Differentiated small‑molecule metabolic disease therapy for durable weight loss with improved tolerability
- Next steps: Joint discovery/optimisation, then development under licensing framework
What happened?
InterAx Biotech and Alveus Therapeutics have entered a strategic research collaboration and licensing agreement to co‑develop a small‑molecule metabolic disease candidate designed to achieve durable weight loss with a better tolerability profile than current options. The deal combines co‑discovery responsibilities with a licensing structure that will allow Alveus (or one partner) to take the lead on later‑stage development and commercialisation under agreed financial terms.
Why does it matter?
Rapid uptake of injectable and now oral incretin‑based therapies has highlighted both the demand for effective obesity treatments and the drawbacks of GI side‑effects, injectable administration and long‑term tolerability challenges. A differentiated small‑molecule approach—if it can sustain clinically meaningful weight loss with fewer adverse effects—could offer an attractive alternative or complement, potentially improving adherence and broadening access.
Who’s behind it?
InterAx Biotech applies computational and systems‑pharmacology approaches to optimise GPCR and signalling‑pathway‑targeted small molecules, aiming for precise pathway bias and improved safety. Alveus Therapeutics focuses on metabolic and related disorders, bringing disease biology, clinical development and commercial strategy expertise in obesity and cardiometabolic indications.
How was it achieved?
Under the collaboration, InterAx and Alveus will jointly identify, design and optimise lead small molecules using InterAx’s signalling‑focused discovery tools aligned with Alveus’ target and indication strategy. The licensing component is expected to include an upfront payment, research funding, development and commercial milestones, and royalties on net sales, reflecting standard risk‑sharing in early metabolic R&D.
What’s next?
The partners will advance lead optimisation and preclinical profiling, aiming to nominate a development candidate that demonstrates robust weight‑loss efficacy with an improved safety and tolerability profile in relevant models. If successful, the programme could progress into first‑in‑human studies as part of a growing wave of non‑incretin, small‑molecule approaches to obesity and metabolic disease.